Focus Equities

BioLineRx Files to Start Phase 3 Study


BioLineRx said Monday that it has filed regulatory submissions it needs in order to commence a randomized, controlled phase 3 registrational trial of BL-8040 for the mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma. The trial is expected to commence by the end of 2017, following receipt of regulatory approvals.

BL-8040 is a short peptide for the treatment of acute myeloid leukemia, solid tumors, and stem cell mobilization. It functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival.